ArticleScientific reports2025
Phytobacter sp. RSE02 is a rice seed endophytic plant probiotic bacterium with human probiotic features and cholesterol-lowering ability.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Folate and the Human Enteric Microbiome: Biological Mechanisms and Clinical Implications.International journal of molecular sciences · 2026Pooled it
- An indole dimer antifungal metabolite from a rice seed endophyte inhibits ergosterol biosynthesis in fungal pathogens.Applied and environmental microbiology · 2026Article
- A comprehensive review on bacterial endophytic secondary metabolites: a road map from crude extract to lead molecule production.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on seed microbiota has gained significant attention due to its role as a primary inoculum that enhances seedling growth, fitness, and productivity. This study explores the characteristics of the plant-probiotic seed-endophyte Phytobacter sp. RSE02, which demonstrates distinctive beneficial probiotic features in animal models. We examine the safety and probiotic potential of RSE02 in human cell lines, zebrafish, and mice. Notably, RSE02 can utilize cholesterol as its sole carbon source; however, it does not adhere to the Caco-2 cell line or the zebrafish gut. Importantly, RSE02 is non-toxic across all tested models. We further explore its cholesterol-utilizing ability to determine its efficacy in mitigating hypercholesterolemia and body fat deposits in mice when administered orally. In a high-fat diet mouse model, RSE02 significantly lowered blood cholesterol levels and reduced body weight, peritoneal fat deposits, and liver weight. Additionally, the treatment with RSE02 led to decreased levels of total blood protein, MDA, and GSH in high-fat diet mice. Genomic analysis of RSE02 revealed the absence of virulence or toxin-producing genes while identifying gene clusters responsible for synthesizing key vitamins such as folate, biotin, and vitamin B12. The findings highlight the dual functionality of Phytobacter sp. RSE02 in enhancing plant and animal health, challenging traditional notions of probiotics, and offering prospects for innovative solutions in sustainable agriculture and cardiovascular health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.